PF-05006739 / Pfizer - LARVOL DELTA

CK1 δ/ε Inhibitor PF-05006739 Ameliorates Hepatic Steatosis and Hyperinsulinemia in Dio Mice (ADA 2019) - "Furthermore, this shift in gene expression also correlated with a shift in respiratory exchange ratio (RER) and energy expenditure (EE) in vivo. Taken together these data suggest CK1 δ/ε inhibition as a potential therapeutic approach for metabolic diseases, specifically hyperinsulinemia and NAFLD/NASH."

Preclinical